Navigation Links
Multiple Sclerosis Drug Trial Criteria to Be Redefined

The tragic death of Anita Louise, a participant of the experimental multiple sclerosis drug trial in 2002 has been brought back to focus by two neurologists from Stanford University//. The authors warn about the dangers associated with drug testing, more so when the adverse effects of the experimental drug is unknown.

The drug natalizumab, marketed under the brand name was granted fast track status by the FDA in 2004. Soon after the approval, the drug use was found to be associated with a potentially fatal infection, progressive multifocal leukoencephalopathy (PML). The observation of infection in a patient who was devoid of the disease prompted the researchers to investigate further.

The researchers argue that healthy volunteers should not be allowed to participate in such drug trials, as they do not derive any benefit out of it. Furthermore, they feel that drugs associated with a risk of death should only be used in patients diagnosed with the disease, after all possible treatments have been found to be ineffective.

Multiple sclerosis is the manifestation of myelin sheath destruction surrounding the nerve cells. The immune system cells attack the myelin sheath, eventually leading to loss of control over motor function and even paralysis. The drug was found to block this effect.

It was highlighted that the inhibition of immune cells, could lead to an increased susceptibility to infections. In fact, PML is an infection that usually affects immunocompromised individuals such as transplant recipients, AIDS victims etc.

The drug was withdrawn from clinical use three months following its approval. With this being the situation, the FDA has taken up the re-approving of the drug as a single therapy. The advisory panel members would get together on the 7th and 8th of March to discuss the issue.

'A big mistake was made in these trials that, in my opinion, is easily preventable. All they need to do is t ighten up entry criteria into multiple sclerosis clinical trials and we could avoid similar types of problems in other trials,' concluded Langer-Gould, one f the senior researchers involved in the study.


'"/>




Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology: